Evogene Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EVGN research report →
Range $2.15 – $2.15
Price Chart
About the company
Evogene Ltd. , along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform.
- CEO
- Ofer Haviv
- IPO
- 2010
- Employees
- 52
- HQ
- Rehovot, HM, IL
Get TickerSpark's AI analysis on EVGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.83M
- P/E
- -0.43
- PEG
- 0.00
- P/S
- 2.79
- P/B
- -2.29
- EV/EBITDA
- 0.11
- Div Yield
- 0.00%
- Gross Margin
- 30.93%
- Op Margin
- -757.22%
- Net Margin
- -639.39%
- ROE
- 937.72%
- ROIC
- -100.84%
Latest fiscal year · YoY change
- Revenue
- $3.85M-30.9%
- Gross Profit
- $-241,000-107.5%
- Op Income
- $-14,034,000
- Net Income
- $-8,485,000+48.5%
- EPS
- $-1.08+62.6%
- OCF Growth
- +31.5%
- FCF Growth
- +32.9%
- 52W High
- $1.50
- 52W Low
- $0.37
- 50D MA
- $0.54
- 200D MA
- $0.83
- Beta
- 0.78
- RSI (14)
- 48
- Avg Volume
- 1.89M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the EVGN Q2 '26 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 106.9%
- Shares Outstanding
- 8.62M
- Float Shares
- 9.21M
of shares held by institutions
28 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Eidelman Virant Capital | 117.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 11, 26 | RECANATI LEON | buy | 460,000 |
| Aug 4, 26 | RECANATI LEON | buy | 800,000 |
| Feb 3, 26 | Ravzin Polina | other | 3,000 |
| Apr 1, 26 | Ravzin Polina | other | 1,500 |
| Apr 1, 26 | Ravzin Polina | other | 6,000 |
| Apr 1, 26 | Ravzin Polina | other | 9,500 |
| Mar 18, 26 | RECANATI LEON | other | 0 |
| Jun 11, 20 | RECANATI LEON | other | 250 |
| Jun 11, 21 | RECANATI LEON | other | 250 |
| Jun 11, 22 | RECANATI LEON | other | 250 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EVGN coverage
Recent articles, reports, and earnings notes.
No research on EVGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EVGN report →Evogene Ltd. (EVGN) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 18
Evogene Reports Second Quarter and First Half 2026 Financial Results
prnewswire.com · Aug 18
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
prnewswire.com · Aug 14
Evogene (NASDAQ:EVGN) Stock Price Passes Below 200 Day Moving Average – Here’s Why
defenseworld.net · Aug 4
Evogene Schedules Second Quarter 2026 Financial Results Release
prnewswire.com · Jul 30
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases
prnewswire.com · Jul 22
AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities
prnewswire.com · Jul 15
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery
prnewswire.com · Jul 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.